anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The investigators will enroll 100 participants in a two-armed randomized controlled trial of the ADAPT platform (iCBT). Participants will be randomly assigned to receive either the ADAPT platform (treatment) or a similar self-guided platform (control) that contains the didactic material (learning) but lacks the ADAPT platforms "crowd" features. Participants will use their assigned platform for a treatment period of 8 weeks. Participants will receive trial assessments at baseline, week 4, and week 8 (post-treatment). Follow-up evaluations will occur at 16 weeks to evaluate maintenance of gains. This pilot effectiveness trial aims to determine the impact on symptoms of depression and anxiety and whether the platform engages the putative targets of personal relevance, relationship, resulting in increased skills mastery and skills use.
This group will receive 2 mg (\>200lbs), 1.5mg (150-200lbs.) or 1 mg (\< 150lbs. of risperidone oral solution on the first day and a placebo on the second day.
The invention discloses a medicament for treating a porcine respiratory disease and a preparation method of the medicament. The medicament for treating the porcine respiratory disease consists of the following Chinese medicinal herb raw materials: rhubarb, coptis root, baikal skullcap root, amur corktree bark, asiatic moonseed rhizome, dandelion, liquoric root, gypsum, airpotato yam, virgate wormwood herb, purpleflower holly leaf, Chinese thorowax root and Chinese ephedra. The preparation method of the medicament for treating the porcine respiratory disease comprises the following steps of: weighing a certain amount of each Chinese medicinal herb raw material; and smashing, sieving and mixing into powder. The medicament for treating the porcine respiratory disease is suitable for symptoms such as porcine triple warmer and high fire, cough with lung heat, jaundice with damp-heat pathogen, swelling and pain in throat, aphtha of the mouth and tongue and the like. As proved by large-scale application, the curative ratio is over 82 percent, and the effective ratio is over 95 percent. The medicament disclosed by the invention belongs to a pure Chinese medicinal preparation; and compared with a western medicament, the medicament has the advantages of freeness from medicinal residues and toxic and side effects.
The invention discloses a composition for treating toothache and a preparation method thereof, belonging to the technical field of Chinese herbal medicines. The composition takes antibacterial, anti-inflammatory, analgesic and teeth strengthening as main treatment rules. The components: raw rhubarb, gypsum, rhizoma drynariae, eucommia bark, green salt, alum, dried alum, angelica, honeysuckle and dandelion. The composition for treating toothache is mainly used for treating tooth pain, gingival bleeding, dental calculus, stabilizing teeth, improving odontoseisis and the like. When the composition for treating toothache is used, the buccal composition is adopted. It is administered orally for 3-5 min. The preparation method of the composition for treating toothache is simple and convenient, and can ensure that the composition effect reaches the maximum on the premise of greatly reducing the loss of raw materials and the loss of effective components.
During the premarketing development of LAMICTAL, 20 sudden and unexplained deaths were recorded among a cohort of 4,700 patients with epilepsy (5,747 patient-years of exposure).

Some of these could represent seizure-related deaths in which the seizure was not observed, e.g., at night. This represents an incidence of 0.0035 deaths per patient-year. Although this rate exceeds that expected in a healthy population matched for age and sex, it is within the range of estimates for the incidence of SUDEP in patients not receiving LAMICTAL (ranging from 0.0005 for the general population of patients with epilepsy, to 0.004 for a recently studied clinical trial population similar to that in the clinical development program for LAMICTAL, to 0.005 for patients with refractory epilepsy). Consequently, whether these figures are reassuring or suggest concern depends on the comparability of the populations reported upon with the cohort receiving LAMICTAL and the accuracy of the estimates provided. Probably most reassuring is the similarity of estimated SUDEP rates in patients receiving LAMICTAL and those receiving other AEDs, chemically unrelated to each other, that underwent clinical testing in similar populations. This evidence suggests, although it certainly does not prove, that the high SUDEP rates reflect population rates, not a drug effect.
Target enrollment of subjects with AUD who regularly engage in risk alcohol consumption (i.e. \>6/day or more heavy alcohol consumption in the 4 weeks preceding the screening visit), and have selected genotypes (LL/TT genotype and/or 1, 2 or 3 of the SNPs on the genes for the 5-HT3 receptor subunits: rs1150226-AG or rs1176713-GG in the gene that encodes the 5-HT3A receptor subunit, and rs17614942-AC in the gene that encodes the 5-HT3B receptor subunit), and who are eligible to participate in the study based on meeting the remaining study inclusion/exclusion criteria. Eligible subjects will be randomized to receive either 0.33 mg AD04 or placebo BID for 24 weeks.

The trial will have a 16-week grace period to enable medication effects to be optimal for comparison with placebo. The grace period starts immediately after beginning of study drug treatment, in which consumption of alcohol is not counted as a failure. All primary and secondary efficacy endpoints will be assessed during the last 8 weeks of treatment (i.e. weeks 17-24). The primary measure of efficacy, incidence risk alcohol consumption, will be assessed over the last 8 weeks of treatment. The secondary measure of efficacy evaluating the incidence of risk alcohol consumption over the last 4 weeks of treatment, important because it has been used commonly to validate efficacy for regulatory agencies such as the European Medicines Agency, was also calculated. To enhance study feasibility, subjects will be evaluated every week during the first 8 weeks of treatment and every other week for the remaining 16 weeks of the treatment period.
A functional cellular framework for sex and estrous cycle-dependent gene expression and behavior is provided, where sex hormone (SH) sensitive neurons are shown to regulate sextypical behaviors. Using orthogonal sequencing approaches, differential expression events are between sexes or estrous states in four SH sensitive populations. These differentially expressed genes (DEGs) are distributed across transcriptionally-defined cell types (tCTs). Two tCTs: BNSTTac1/Esr1 and VMHvlCckar/Esr1 are essential for sex recognition in males and mating in females, respectively. Projections of the VMHvlCckar/Esr1 tCT are distinct from those of other tCTs in this SH-sensitive population. It is further shown that POA neurons expressing the substance P receptor Tacr1 (POATacr1) are responsible for initiating mating in males. A specific subpopulation of neurons in the female, AVPVKISS1, are necessary and sufficient for female sexual behavior, and receive monosynaptic inputs from Cckar neurons.
ENGERIX-B [Hepatitis B Vaccine (Recombinant)] is a noninfectious recombinant DNA hepatitis B vaccine developed and manufactured by GlaxoSmithKline Biologicals. It contains purified surface antigen of the virus obtained by culturing genetically engineered Saccharomyces cerevisiae cells, which carry the surface antigen gene of the hepatitis B virus. The surface antigen expressed in Saccharomyces cerevisiae cells is purified by several physicochemical steps and formulated as a suspension of the antigen adsorbed on aluminum hydroxide. The procedures used to manufacture ENGERIX-B result in a product that contains no more than 5% yeast protein. No substances of human origin are used in its manufacture.

ENGERIX-B is supplied as a sterile suspension for intramuscular administration. The vaccine is ready for use without reconstitution; it must be shaken before administration since a fine white deposit with a clear colorless supernatant may form on storage.

ENGERIX-B is formulated without preservatives.
Randomly selected patients,(ratio 1:1) with newly begun mechanical ventilation, will be connected to a low energy acustic wave generator UROSHIELD® within 48 hours. Endotracheal secretions will be collected for culture and antibiotic sensitivity every 3 days for 15 consecutive days or until disconnection from the mechanical ventilation.
After antimicrobial susceptibility testing of Helicobacter pylori from biopsy samples, according to antibiotic resistance pattern of each one, give esomeprazole 20mg bid and two sensitive ones of amoxicillin,clarithromycin, metronidazole,and levofloxacin. All regimens will be given for 14 days.
Triacylglyceride (TAG) synthesis in the small intestine determines the absorption of dietary fat, but the underlying mechanisms remain to be further studied. Here, we report that the RNA-binding protein HuR (ELAVL1) promotes TAG synthesis in the small intestine. HuR associates with the 3' UTR of Dgat2 mRNA and intron 1 of Mgat2 pre-mRNA. Association of HuR with Dgat2 3' UTR stabilizes Dgat2 mRNA, while association of HuR with intron 1 of Mgat2 pre-mRNA promotes the processing of Mgat2 pre-mRNA. Intestinal epithelium-specific HuR knockout reduces the expression of DGAT2 and MGAT2, thereby reducing the dietary fat absorption through TAG synthesis and mitigating high-fat-diet (HFD)-induced non-alcoholic fatty liver disease (NAFLD) and obesity. Our findings highlight a critical role of HuR in promoting dietary fat absorption.
BACKGROUND: Depression affects a significant portion of the global population and has emerged as one of the most debilitating conditions worldwide. Recent studies have explored the relationship between depression and the microbiota of the intestine, revealing potential avenues for effective treatment.
METHODS: To evaluate the potential alleviation of depression symptoms, we employed a depression C57BL/6 mice model induced by chronic unpredictable mild stress (CUMS). We administered Lactiplantibacillus plantarum JYLP-326 and conducted various animal behavior tests, including the open-field test (OFT), sucrose preference test (SPT), and tail-suspension test (TST). Additionally, we conducted immunohistochemistry staining and analyzed the hippocampal and colon parts of the mice.
RESULTS: The results of the behavior tests indicated that L. plantarum JYLP-326 alleviated spontaneous behavior associated with depression. Moreover, the treatment led to significant improvements in GFAP and Iba1, suggesting its potential neuroprotective effects. Analysis of the hippocampal region indicated that L. plantarum JYLP-326 administration upregulated p-TPH2, TPH2, and 5-HT1AR, while downregulating the expression of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α. In the colon, the treatment inhibited the TLR4-MyD88-NF-κB pathway and increased the levels of occludin and ZO-1, indicating improved intestinal barrier function. Additionally, the probiotic demonstrated a regulatory effect on the HMGB1-RAGE-TLR4 signaling pathway.
CONCLUSIONS: Our findings demonstrate that L. plantarum JYLP-326 exhibits significant antidepressant-like effects in mice, suggesting its potential as a therapeutic approach for depression through the modulation of gut microbiota. However, further investigations and clinical trials are required to validate its safety and efficacy for human use.
Comprehensive surgical staging for endometrial carcinoma(EC) is an indisputable staging and prognostic tool. The staging procedure includes total hysterectomy, bilateral salpingo-oophorectomy, and lymphadenectomy, omental biopsy if necessary. Since lymph node metastasis is one of the most important risk factors of prognosis. The dissection of lymph nodes has been used for staging, prognostic information, and to determine the need for adjuvant therapy. The approach to lymph node evaluation in women with EC is still a subject of debate. Practice varies across different institutions or surgeons. In general, the options for management of retroperitoneal lymph nodes include no lymph node dissection (LND), systematic LND only if the risk of lymph node metastasis exceeds a certain threshold, or routine sentinel LND following lymphatic mapping. lymphadenectomy is significantly associated with longer operating time, higher surgical costs, greater rate of infection, as well as the occurrence of lymphocysts and lymphedema, moreover, there is lack of evidence of a therapeutic benefit of LND, less invasive techniques have emerged as possible alternatives. The technique for lymphatic mapping and sentinel lymph node dissection (SLND) in EC has been refined and found a low false-negative rate for detection of positive lymph nodes. The 2018 National Comprehensive cancer Network (NCCN) guideline of uterus cancer states SLN mapping can be considered for the surgical staging of apparent uterine-confined malignancy when there is no metastasis demonstrated by imaging studies or no obvious extrauterine disease at exploration. It indicates low-risk patients could avoid those side effects of the systematic Lymph node dissection. Whether high-risk patients (grade 3, deep myometrial invasion, non-endometrioid endometrial cancer, and Cervical invasion) can be benefited from this technique? This prospective cohort study is designed to To evaluate the efficacy of sentinel lymph node biopsy technique in patients with high-risk endometrial carcinoma. Surgery should be performed within a maximum of 4 weeks from the patient's first consultation.
Intentional overdosage has been reported rarely with metolazone and similar diuretic drugs.   
Signs And Symptoms    
Orthostatic hypotension, dizziness, drowsiness, syncope, electrolyte abnormalities, hemoconcentration and hemodynamic changes due to plasma volume depletion may occur. In some instances depressed respiration may be observed. At high doses, lethargy of varying degree may progress to coma within a few hours. The mechanism of CNS depression with thiazide overdosage is unknown. Also, GI irritation and hypermotility may occur. Temporary elevation of BUN has been reported, especially in patients with impairment of renal function. Serum electrolyte changes and cardiovascular and renal function should be closely monitored.   
Treatment    
There is no specific antidote available but immediate evacuation of stomach contents is advised. Dialysis is not likely to be effective. Care should be taken when evacuating the gastric contents to prevent aspiration, especially in the stuporous or comatose patient. Supportive measures should be initiated as required to maintain hydration, electrolyte balance, respiration, and cardiovascular and renal function.
The invention discloses a special-effect traditional Chinese medicine for treating bleeding wounds and a preparation method and application thereof. The medicine is prepared from, by weight, 5-10 parts of Polygonum suffultum Maxim. rhizome and 5-10 parts of coptis chinensis, and 3-9 parts of rhizome or mature fruit of Trillium tschonoskii Maxim, 10-15 parts of Garden Balsam stems and 6-10 parts of common bletilla rubber can also be added. The preparation method includes the steps of weighing the traditional Chinese medicine raw materials according to the ratio, drying, smashing and screening the materials, and adding medicinal alcohol to be mixed with the materials into paste to obtain the medicine when the medicine needs to be used. Rapid and effective hemostasis can be achieved when wounds are coated with the medicine. Polygonum suffultum Maxim. rhizome and coptis chinensis are selected and have a synergistic effect after being combined according to the ratio, and the treatment effect can be remarkably improved. The medicine conforms to the simple, convenient, cheap and efficient pharmacy standards, can achieve astringency and hemostasis, relieve pain, promote tissue regeneration, eliminate stagnant blood and promote circulation of qi, and can be widely applied to trauma bleeding caused by various knife wounds, nail injuries, scratches, glass fragment scratching, movement falling injuries and the like.
This is a randomized, double-blinded, placebo-controlled phase 2 clinical trial to evaluate immunogenicity and safety of IRV performed in 600 subjects (aged 2-71 months). Then, 300 toddlers (aged 7-71 months) and 300 infants (aged 2-6 months) will be eligible for parallel enrollment after assessing through medical history and physical examination. Subjects from each age group will be randomly assigned to the vaccine group or placebo group in a ratio of 3:1, that is, 225 subjects of all age groups will be injected with the vaccine while 75 subjects with the placebo.

Toddlers (aged 7-71 months) will receive an injection of the vaccine or placebo in the anterolateral midthigh or deltoid muscle of the upper arm on Day 0 and 28. Infants (aged 2-6 months) will receive an injection of the vaccine or placebo in the anterolateral midthigh or deltoid muscle of the upper arm on Day 0, 28, and 56. There would be 140 subjects in each age group chosen voluntarily for the immune persistence cohort according to the order of enrollment. The duration of toddlers (aged 7-71 months) for intervention is approximately 1 month. Thus, the duration of each subject enrolled in the immune persistence cohort will be approximately 13 months while the duration of the rest of the subjects in the study will be approximately 7 months. The duration of infants (aged 2-6 months) for intervention is approximately 2 months. Thus, the duration of each subject enrolled in the immune persistence cohort will be approximately 14 months while the duration of the rest of the subjects in the study will be approximately 8 months.

For safety assessment, the observation and evaluation of adverse events (AE) from Day 0 to Days 28/30 after each dose, and serious adverse events (SAE) between the first dose up to 6 months after the final dose will be evaluated by diary/contact cards, active reports by subjects' legal guardians, or investigators' phone calls as well as face-to-face visits. Meanwhile, subjects will be observed at the site for at least 30 minutes after each dose. For immunogenicity assessment, neutralizing antibodies against the strain from which the vaccine is based (homologous ZTR-68 strain (G1P\[8\]), IgG antibodies, IgA antibodies of all subjects, and neutralizing antibodies against the G3 and G9 type RV in 140 subjects of each age group will be assessed. For the exploratory endpoint, the gene transcription level of PBMC will be examined for the preliminary exploration of the possible mechanism of the Inactivated Rotavirus Vaccine (Vero Cells).
TDCS intervention protocol consists of 10 sessions of 20 minutes of 1.5 mA electrical stimulation on consecutive days. Anodal electrode will be placed over the left dorsolateral prefrontal cortex and cathodal electrode will be placed over the right supraorbital area.
Remifentanil infusion rate is adjusted according to the conventional method of blood pressure and heart rate monitroing. Blood pressure and heart rate are controlled to be within 20% of baseline. We will not monitor ANI in this group.
PURPOSE: A multi-layered anti-tissue adhesion membrane is provided to stably place on wound and to protect wound. CONSTITUTION: A multilayered anti-tissue adhesion membrane is formed by laminating tissue adhesion layer of microfiber form and lubricant. The tissue adhesion layer of microfiber form is prepared using biocompatible polymer. The lubricant contains polysaccharide polymers. The thickness of the tissue adhesion layer is 0.1-1,000 um. The thickness of lubricant is 1-1,000 um. The multi-layered structure is two layer structure of the tissue adhesion layer and lubricant layer; or three layer structure of the tissue adhesion layer, lubricant layer, and tissue adhesion layer.
Twelve additional volunteers will participate in part B, receiving 4 x 18 MIU biosimilar interferon beta-1a with albumin as s.c. doses at 48 hours intervals as 3 pre-filled syringes (3 sites 1 cm apart in abdominal wall on each dosing day, alternating right side for odd dose \[i.e. dose 1 and 3\] and left side for even dose \[i.e. dose 2 and 4\]).
PURPOSE:To provide a hair tonic containing cis-6,cis-9,cis-12-octadecatrienoic acid as an active ingredient, exhibiting remarkable hair-growth promoting effect, stably storable for a long period and effective in preventing sebum secretion and dandruff on scalp. CONSTITUTION:The objective hair tonic contains cis-6,cis-9,cis-12-octadecatrienoic acid as an active ingredient. It is used in the form of hair tonic, hair lotion, etc., by using a proper amount of a base such as water, an alcohol (e.g. ethanol), a polyhydric alcohol (e.g. glycerol), liquid paraffin, etc. The amount of the active ingredient in the hair tonic is usually 0.001-10wt%, preferably 0.01-3wt% based on the whole composition. The active ingredient is a kind of essential fatty acid existing in cell membrane of microorganism of Mortierella genus, etc., or in evening primrose oil, etc., and can be obtained e.g. by extraction.
PURPOSE:To obtain the subject new protein useful for nervous information transmission in the synapsis, the development of synaptic plasticity to be a basis for the memory and learning and elucidation of nervous cell necrosis, etc., of cerebral ischemia and epilepsy, etc., and treatment, etc., of genetic diseases. CONSTITUTION:A murine cerebrum and cerebellum are homogenized in an aqueous solution of guanidium thiocyanate to extract an RNA by a conventional method. The resultant RNA is then subjected to the oligo(dT)-cellulose column chromatography to separate an mRNA, which is then used as a template to synthesize a cDNA. A cDNA library is further prepared by the conventional method and then screened with a labeled probe composed of a part of a base sequence in a gene capable of coding a glutamic acid receptor. A positive clone is subsequently selected to recover the DNA thereof, which is then treated with a restriction enzyme and bound to a vector. The obtained lambda phage particle having the recombinant lambda phage DNA is subsequently transduced into a host cell and transformation is carried out. The resultant transformant is further cultured to afford the objective new protein which is the glutamic acid receptor having a specific amino acid sequence.
FIELD: organic chemistry. SUBSTANCE: invention relates to pharmaceutical composition as emulsion or solution that shows IMMUNOSUPPRESSIVE effect and has compound of the formula (I)   as an active component that is given in description text. Composition has the special additions - emulsifier and lipophilic agent. Emulsifier - substance taken from the group involving egg yolk lecithin, soybean lecithin, products of their hydrogenization, phosphatitylcholine, phosphatidylserine, gum arabic, gelatin, castor oil hardened with polyhydroxyethylene, ester of polyhydroxyethylenesorbitane and fatty acid, ester of polyhydroxyethylene and fatty acid, mono- and diglycerides of fatty acids with the mean chain length and polyhydroxyethylated glyceride. Lipophilic agent is taken from the group: soybean, sesame, cotton, safflower, corn, rape, peanut oils, fatty acid triglycerides with the mean chain length and liquid hydrocarbons. Content of compound (I) is 0.05-50 mg/ml, lipophilic agent - 5-20 wt.-%, mass ratio of emulsifier : lipophilic agent = 0.5-400:100. Composition can contain additionally organic solvent at amount 0.002-2 ml, preferably, 0.01-1 ml, or 0.02-0.5 ml/1 mg compound (I) and can present the solution. Composition can be prepared as emulsion "oil-in-water" and has water additionally. Composition is prepared by components mixing. Composition can be used in medicine at organ transplantation. EFFECT: improved method of synthesis. 11 cl, 2 tbl